RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC

The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news